AJP - Endo AJP: Renal Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (April 18, 2006). doi:10.1152/ajpendo.00600.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/E483    most recent
00600.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toth, M. J
Right arrow Articles by Casson, P. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toth, M. J
Right arrow Articles by Casson, P. R
Submitted on December 1, 2005
Accepted on April 9, 2006

Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein metabolism in women

Michael J Toth1*, Cynthia K Sites2, Dwight E Matthews1, and Peter R Casson1

1 Department of Medicine, University of Vermont, Burlington, United States
2 Department of Obstetrics and Gynecology, University of Vermont, Burlington, United States

* To whom correspondence should be addressed. E-mail: michael.toth{at}uvm.edu.

The age-related decline in fat-free mass is accelerated in women after menopause. The role of ovarian hormone deficiency in the regulation of fat-free mass, however, has not been clearly defined. To address this question, we examined the effect of ovarian hormone suppression on whole body protein metabolism. Whole body protein breakdown, oxidation and synthesis were measured using [13C]leucine in young, healthy women with regular menstrual patterns before and after two months of treatment with gonadotropin-releasing hormone agonist (GnRHa; n=6) or placebo (n=7). Protein metabolism was measured under postabsorptive and euglycemic-hyperinsulinemic-hyperaminoacidemic conditions. Ovarian suppression did not alter whole body or regional fat-free mass or adiposity. In the postabsorptive state, GnRHa administration was associated with reductions in protein breakdown and synthesis (P<0.05); whereas, no change in protein oxidation was noted. Under euglycemic-hyperinsulinemic-hyperaminoacidemic conditions, a similar reduction (P<0.05) in protein synthesis and breakdown was noted; whereas, protein oxidation increased (P<0.05) in the placebo group. Testosterone, steroid hormone precursors, insulin-like growth factor-I and their respective binding proteins were not altered by GnRHa administration and changes in these hormones over time were not associated with GnRHa-induced alterations in protein metabolism, suggesting that changes in protein turnover are not due to an effect of ovarian suppression on other endocrine systems. Our findings provide evidence that endogenous ovarian hormones participate in the regulation of protein turnover in women.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.